DocDollars

Sumitomo Pharma America, Inc.

MA · United States · Reporting entity ID 100001316929

Total reported 2019–2025
$134.6M
#76 of 2,960 reporting companies — 0.2% of all reported industry payments
$13.9M in general payments across 312,682 records, plus $120.8M in research funding across 36,747 records.

How it breaks down

General payments $13,859,698
Research funding $120,753,956

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Sumitomo Pharma America, Inc. reported $134.6M to US doctors and teaching hospitals from 2019 to 2025, ranking #76 of 2,960 reporting companies. 90% of that was research funding and 10% general payments such as consulting, speaking, food and travel. 312,682 general payment records and 36,747 research records were filed.

Common questions about Sumitomo Pharma America, Inc.

How much has Sumitomo Pharma America, Inc. paid US doctors?

Sumitomo Pharma America, Inc. reported $134,613,653 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $13,859,698 in general payments, $120,753,956 in research funding.

How does Sumitomo Pharma America, Inc. rank among drug and device companies?

It ranks #76 of 2,960 reporting entities by total reported value, about 0.2% of all industry payments in the dataset.

Does a payment from Sumitomo Pharma America, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.